Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (83) 83
index medicus (73) 73
oncology (70) 70
female (64) 64
male (58) 58
middle aged (55) 55
aged (49) 49
adult (40) 40
aged, 80 and over (29) 29
human necessities (29) 29
hygiene (29) 29
medical or veterinary science (29) 29
preparations for medical, dental, or toilet purposes (29) 29
cancer (27) 27
chemotherapy (27) 27
article (25) 25
mutation (25) 25
treatment outcome (23) 23
care and treatment (22) 22
adenocarcinoma (20) 20
tumors (20) 20
radiotherapy (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (16) 16
prognosis (16) 16
mutations (15) 15
retrospective studies (15) 15
specific therapeutic activity of chemical compounds ormedicinal preparations (15) 15
surgery (15) 15
therapy (15) 15
research (14) 14
survival (14) 14
cell lung-cancer (13) 13
neoplasm staging (13) 13
abridged index medicus (12) 12
protein kinase inhibitors - therapeutic use (12) 12
animals (11) 11
antineoplastic agents - therapeutic use (11) 11
mice (11) 11
pancreatic cancer (11) 11
analysis (10) 10
deoxycytidine - analogs & derivatives (10) 10
gemcitabine (10) 10
gene amplification (10) 10
hematology, oncology and palliative medicine (10) 10
neoplasms - drug therapy (10) 10
phase-ii (10) 10
pyrazoles - therapeutic use (10) 10
pyridines - therapeutic use (10) 10
survival rate (10) 10
trial (10) 10
adenocarcinoma - pathology (9) 9
adenocarcinoma - therapy (9) 9
chemoradiation (9) 9
chemoradiotherapy (9) 9
expression (9) 9
health aspects (9) 9
lung neoplasms - drug therapy (9) 9
medicine & public health (9) 9
neoadjuvant therapy (9) 9
pancreatic neoplasms - drug therapy (9) 9
pancreatic neoplasms - pathology (9) 9
adenocarcinoma - genetics (8) 8
adenocarcinoma - mortality (8) 8
capecitabine (8) 8
carcinoma, non-small-cell lung - drug therapy (8) 8
colorectal cancer (8) 8
disease-free survival (8) 8
egfr (8) 8
fluorouracil - administration & dosage (8) 8
lung neoplasms - genetics (8) 8
metastasis (8) 8
pancreatic neoplasms - mortality (8) 8
patients (8) 8
bevacizumab (7) 7
carcinoma, non-small-cell lung - genetics (7) 7
colorectal neoplasms - drug therapy (7) 7
dose-response relationship, drug (7) 7
follow-up studies (7) 7
gefitinib (7) 7
genetic aspects (7) 7
nuclear radiation (7) 7
original reports (7) 7
proto-oncogene proteins c-met - genetics (7) 7
receptor, epidermal growth factor - genetics (7) 7
stomach cancer (7) 7
young adult (7) 7
acquired-resistance (6) 6
adenocarcinoma - surgery (6) 6
carcinoma (6) 6
carcinomas (6) 6
colon-cancer (6) 6
colorectal neoplasms - genetics (6) 6
combined modality therapy (6) 6
deoxycytidine - administration & dosage (6) 6
esophageal cancer (6) 6
fluorouracil - analogs & derivatives (6) 6
genotype (6) 6
in situ hybridization, fluorescence (6) 6
kaplan-meier estimate (6) 6
liver neoplasms - secondary (6) 6
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (190) 190
French (7) 7
Chinese (4) 4
German (4) 4
Korean (2) 2
Portuguese (2) 2
Danish (1) 1
Greek (1) 1
Norwegian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Pancreatic ductal adenocarcinoma: Is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?
by Konstantinidis, Ioannis T and Warshaw, Andrew L and Allen, Jill N and Blaszkowsky, Lawrence S and Castillo, Carlos Fernandez-Del and Deshpande, Vikram and Hong, Theodore S and Kwak, Eunice L and Lauwers, Gregory Y and Ryan, David P and Wargo, Jennifer A and Lillemoe, Keith D and Ferrone, Cristina R
Annals of Surgery, ISSN 0003-4932, 04/2013, Volume 257, Issue 4, pp. 731 - 736
Objective: Patients who undergo an R0 resection of their pancreatic ductal adenocarcinoma (PDAC) have an improved survival compared with patients who undergo... 
pancreatic adenocarcinoma | R1 resections | locally advanced | 1-mm margin | SURGERY | COMPARING STANDARD PANCREATICODUODENECTOMY | SURGEONS CONTRIBUTION | MINIMAL POSTOPERATIVE COMPLICATIONS | LONG-TERM SURVIVAL | EXTENDED LYMPHADENECTOMY | SURGICAL-TREATMENT | RANDOMIZED CONTROLLED TRIAL | PERIAMPULLARY ADENOCARCINOMA | QUALITY-OF-LIFE | SINGLE-INSTITUTION EXPERIENCE | Adenocarcinoma - pathology | Prognosis | Humans | Middle Aged | Pancreatic Neoplasms - pathology | Pancreatic Neoplasms - surgery | Male | Survival Rate | Carcinoma, Pancreatic Ductal - pathology | Carcinoma, Pancreatic Ductal - surgery | Young Adult | Aged, 80 and over | Adult | Carcinoma, Pancreatic Ductal - mortality | Female | Aged | Pancreatic Neoplasms - mortality | Adenocarcinoma - mortality | Adenocarcinoma - surgery | Pancreatectomy - methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class i PI3K inhibitor, in patients with advanced solid tumors AC
by Shapiro, Geoffrey I and Rodon, Jordi and Bedell, Cynthia and Kwak, Eunice L and Baselga, Jose and Braña, Irene and Pandya, Shuchi S and Scheffold, Christian and Laird, A. Douglas and Nguyen, Linh T and Xu, Yi and Egile, Coumaran and Edelman, Gerald
Clinical Cancer Research, ISSN 1078-0432, 01/2014, Volume 20, Issue 1, pp. 233 - 245
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text What's the Best Way to Treat GE Junction Tumors? Approach Like Gastric Cancer
by Mullen, JT and Kwak, EL and Hong, TS
ANNALS OF SURGICAL ONCOLOGY, ISSN 1068-9265, 11/2016, Volume 23, Issue 12, pp. 3780 - 3785
The debate as to the optimal classification, staging, and treatment of gastroesophageal junction (GEJ) tumors wages on, and one must acknowledge that there is... 
STAGING SYSTEM | SURGERY | THERAPY | GASTROESOPHAGEAL JUNCTION | ONCOLOGY | ADENOCARCINOMA | CARDIA | PATHOLOGICAL RESPONSE | PREOPERATIVE CHEMORADIOTHERAPY | CLASSIFICATION | ESOPHAGOGASTRIC JUNCTION | ESOPHAGEAL | Humans | Postoperative Period | Stomach Neoplasms - therapy | Esophagectomy | Chemoradiotherapy, Adjuvant | Gastrectomy | Adenocarcinoma - therapy | Esophagogastric Junction - surgery | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Esophageal Neoplasms - therapy | Preoperative Period | Stomach cancer | Squamous cell carcinoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma
by Keane, Florence K and Wo, Jennifer Y and Ferrone, Cristina R and Clark, Jeffrey W and Blaszkowsky, Lawrence S and Allen, Jill N and Kwak, Eunice L and Ryan, David P and Lillemoe, Keith D and Fernandez-Del Castillo, Carlos and Hong, Theodore S
American Journal of Clinical Oncology: Cancer Clinical Trials, ISSN 0277-3732, 2018, Volume 41, Issue 6, pp. 607 - 612
Objectives: Improved outcomes with FOLFIRINOX or gemcitabine with nab-paclitaxel in the treatment of metastatic pancreatic adenocarcinoma (PDAC) have prompted... 
locally advanced pancreatic cancer | radiotherapy | pancreatic cancer | chemotherapy | resection | FOLFIRINOX | CONSOLIDATIVE CHEMORADIATION | PHASE-II | CANCER | GEMCITABINE | RADIATION-THERAPY | STEREOTACTIC RADIOSURGERY | ONCOLOGY | IRREVERSIBLE ELECTROPORATION | Adenocarcinoma - pathology | Prognosis | Follow-Up Studies | Humans | Middle Aged | Induction Chemotherapy | Male | Chemoradiotherapy, Adjuvant - mortality | Laparotomy - mortality | Neoadjuvant Therapy - mortality | Fluorouracil - administration & dosage | Aged, 80 and over | Adult | Female | Retrospective Studies | Deoxycytidine - administration & dosage | Pancreatic Neoplasms - pathology | Survival Rate | Carcinoma, Pancreatic Ductal - therapy | Combined Modality Therapy | Carcinoma, Pancreatic Ductal - pathology | Adenocarcinoma - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intraoperative Care | Aged | Deoxycytidine - analogs & derivatives | Pancreatic Neoplasms - therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Intraoperative Radiotherapy in the Era of IntCensive Neoadjuvant hemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma
by Keane, Florence K and Wo, Jennifer Y and Ferrone, Cristina R and Clark, Jeffrey W and Blaszkowsky, Lawrence S and Allen, Jill N and Kwak, Eunice L
American Journal of Clinical Oncology, ISSN 0277-3732, 06/2018, Volume 41, Issue 6, p. 607
Treatment outcome | Care and treatment | Usage | Pancreatic cancer | Analysis | Radiotherapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib inBRAFV600–Mutant Colorectal Cancer
by Corcoran, Ryan B and Atreya, Chloe E and Falchook, Gerald S and Kwak, Eunice L and Ryan, David P and Bendell, Johanna C and Hamid, Omid and Messersmith, Wells A and Daud, Adil and Kurzrock, Razelle and Pierobon, Mariaelena and Sun, Peng and Cunningham, Elizabeth and Little, Shonda and Orford, Keith and Motwani, Monica and Bai, Yuchen and Patel, Kiran and Venook, Alan P and Kopetz, Scott
Journal of Clinical Oncology, ISSN 0732-183X, 12/2015, Volume 33, Issue 34, pp. 4023 - 4031
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Activity and safety of crizotinib in patients with ALK -positive non-small-cell lung cancer: updated results from a phase 1 study
by Camidge, D Ross, Dr and Bang, Yung-Jue, Prof and Kwak, Eunice L, MD and Iafrate, A John, MD and Varella-Garcia, Marileila, Prof and Fox, Stephen B, Prof and Riely, Gregory J, MD and Solomon, Benjamin, MBBS and Ou, Sai-Hong I, MD and Kim, Dong-Wan, Prof and Salgia, Ravi, Prof and Fidias, Panagiotis, MD and Engelman, Jeffrey A, MD and Gandhi, Leena, MD and Jänne, Pasi A, MD and Costa, Daniel B, MD and Shapiro, Geoffrey I, MD and LoRusso, Patricia, DO and Ruffner, Katherine, MD and Stephenson, Patricia, ScD and Tang, Yiyun, PhD and Wilner, Keith, PhD and Clark, Jeffrey W, MD and Shaw, Alice T, MD
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 10, pp. 1011 - 1019
Summary Background ALK fusion genes occur in a subset of non-small-cell lung cancers (NSCLCs). We assessed the tolerability and activity of crizotinib in... 
Hematology, Oncology and Palliative Medicine | KRAS MUTATIONS | ONCOLOGY | EML4-ALK FUSION GENE | C-MET | KINASE | ACQUIRED-RESISTANCE | ANAPLASTIC LYMPHOMA | CLINICAL-FEATURES | INHIBITOR | REARRANGEMENTS | EGFR | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Lung Neoplasms - enzymology | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Carcinoma, Non-Small-Cell Lung - mortality | Pyridines - adverse effects | Protein Kinase Inhibitors - therapeutic use | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Pyrazoles - adverse effects | Pyridines - therapeutic use | Care and treatment | Safety and security measures | Genes | Oncology, Experimental | Research | Lung cancer, Non-small cell | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text What’s the Best Way to Treat GE Junction Tumors? Approach Like Gastric Cancer
by Mullen, John T and Kwak, Eunice L and Hong, Theodore S
Annals of Surgical Oncology, ISSN 1068-9265, 11/2016, Volume 23, Issue 12, pp. 3780 - 3785
The debate as to the optimal classification, staging, and treatment of gastroesophageal junction (GEJ) tumors wages on, and one must acknowledge that there is... 
Oncology | Medicine & Public Health | Surgical Oncology | Surgery
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Abstract LB-055: Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations
by Ahronian, Leanne G and Sennott, Erin M and Van Allen, Eliezer M and Wagle, Nikhil and Kwak, Eunice L and Faris, Jason E and Godfrey, Jason T and Nishimura, Koki and Lynch, Kerry D and Mermel, Craig H and Lockerman, Elizabeth L and Kalsy, Anuj and Gurski, Joseph M and Bahl, Samira and Anderka, Kristin and Green, Lisa M and Lennon, Niall J and Huynh, Tiffany G and Mino-Kenudson, Mari and Getz, Gad and Dias-Santagata, Dora and Iafrate, A. John and Engelman, Jeffrey A and Garraway, Levi A and Corcoran, Ryan B
Cancer Research, ISSN 0008-5472, 08/2015, Volume 75, Issue 15 Supplement, pp. LB-055 - LB-055
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
by Shaw, Alice T, Dr and Yeap, Beow Y, ScD and Solomon, Benjamin J, MD and Riely, Gregory J, MD and Gainor, Justin, MD and Engelman, Jeffrey A, MD and Shapiro, Geoffrey I, MD and Costa, Daniel B, MD and Ou, Sai-Hong I, MD and Butaney, Mohit, BS and Salgia, Ravi, Prof and Maki, Robert G, MD and Varella-Garcia, Marileila, Prof and Doebele, Robert C, MD and Bang, Yung-Jue, Prof and Kulig, Kimary, PhD and Selaru, Paulina, MSPH and Tang, Yiyun, PhD and Wilner, Keith D, PhD and Kwak, Eunice L, MD and Clark, Jeffrey W, MD and Iafrate, A John, MD and Camidge, D Ross, MD
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 11, pp. 1004 - 1012
Summary Background ALK gene rearrangement defines a new molecular subtype of non-small-cell lung cancer (NSCLC). In a recent phase 1 clinical trial, the ALK... 
Hematology, Oncology and Palliative Medicine | ANAPLASTIC LYMPHOMA KINASE | GEFITINIB | ONCOLOGY | EML4-ALK FUSION GENE | PHASE-III | 2P23 | HISTOLOGY | TUMORS | ACTIVATING MUTATIONS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Lung Neoplasms - mortality | United States | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Patient Selection | Multicenter Studies as Topic | Time Factors | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Retrospective Studies | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Risk Assessment | Carcinoma, Non-Small-Cell Lung - genetics | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Survival Rate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Receptor Protein-Tyrosine Kinases - genetics | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Australia | Clinical Trials, Phase I as Topic | Care and treatment | Analysis | Patient outcomes | Genetic research | Genetic aspects | Lung cancer, Non-small cell | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
by Alice T. Shaw and Beow Y. Yeap and Mari Mino-Kenudson and Subba R. Digumarthy and Daniel B. Costa and Rebecca S. Heist and Benjamin Solomon and Hannah Stubbs and Sonal Admane and Ultan McDermott and Jeffrey Settleman and Susumu Kobayashi and Eugene J. Mark and Scott J. Rodig and Lucian R. Chirieac and Eunice L. Kwak and Thomas J. Lynch and A. John Iafrate
Journal of Clinical Oncology, ISSN 0732-183X, 09/2009, Volume 27, Issue 26, pp. 4247 - 4253
Purpose The EML4-ALK fusion oncogene represents a novel molecular target in a small subset of non-small-cell lung cancers (NSCLC). To aid in identification and... 
ANAPLASTIC LYMPHOMA KINASE | GEFITINIB | GROWTH-FACTOR-RECEPTOR | ONCOLOGY | PHASE-II | FUSION GENE | EGFR MUTATIONS | KRAS | TUMORS | CHEMOTHERAPY | ERLOTINIB | Erlotinib Hydrochloride | Immunohistochemistry | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Oncogene Proteins, Fusion - metabolism | Age Factors | Protein-Tyrosine Kinases - metabolism | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Protein-Tyrosine Kinases - genetics | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Genes, ras - genetics | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Genotype | In Situ Hybridization, Fluorescence | Treatment Outcome | Receptor Protein-Tyrosine Kinases | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Oncogene Proteins, Fusion - genetics | Sex Factors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Original Reports | Thoracic Oncology | Thor12 | To8 | To20
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
by Kwak, Eunice L and Bang, Yung-Jue and Camidge, D. Ross and Shaw, Alice T and Solomon, Benjamin and Maki, Robert G and Ou, Sai-Hong I and Dezube, Bruce J and Jänne, Pasi A and Costa, Daniel B and Varella-Garcia, Marileila and Kim, Woo-Ho and Lynch, Thomas J and Fidias, Panos and Stubbs, Hannah and Engelman, Jeffrey A and Sequist, Lecia V and Tan, WeiWei and Gandhi, Leena and Mino-Kenudson, Mari and Wei, Greg C and Shreeve, S. Martin and Ratain, Mark J and Settleman, Jeffrey and Christensen, James G and Haber, Daniel A and Wilner, Keith and Salgia, Ravi and Shapiro, Geoffrey I and Clark, Jeffrey W and Iafrate, A. John
The New England Journal of Medicine, ISSN 0028-4793, 10/2010, Volume 363, Issue 18, pp. 1693 - 1703
A small group of patients with non–small-cell lung cancer have genetic lesions that activate anaplastic lymphoma kinase (ALK). Crizotinib, an orally... 
ALK | MEDICINE, GENERAL & INTERNAL | GEFITINIB | EML4-ALK FUSION GENE | 2ND-LINE TREATMENT | PHASE-II | IDENTIFICATION | TUMORS | ACTIVATING MUTATIONS | EGFR | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Microtubule-Associated Proteins - genetics | Humans | Middle Aged | Receptors, Growth Factor - antagonists & inhibitors | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Protein-Tyrosine Kinases - genetics | Pyridines - adverse effects | Serine Endopeptidases - genetics | Cell Cycle Proteins - genetics | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Pyridines - administration & dosage | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Kaplan-Meier Estimate | In Situ Hybridization, Fluorescence | Receptor Protein-Tyrosine Kinases | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Care and treatment | Lung cancer, Small cell | Genetic aspects | Diagnosis | Health aspects | Phosphotransferases | Lymphomas | Pharmaceutical industry | Lung cancer | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text The discussants reply
by Hong, Theodore S and Kwak, Eunice L
New England Journal of Medicine, ISSN 0028-4793, 09/2009, Volume 361, Issue 13, pp. 1315 - 1316
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
by Kristin Bergethon and Alice T. Shaw and Sai-Hong Ignatius Ou and Ryohei Katayama and Christine M. Lovly and Nerina T. McDonald and Pierre P. Massion and Christina Siwak-Tapp and Adriana Gonzalez and Rong Fang and Eugene J. Mark and Julie M. Batten and Haiquan Chen and Keith D. Wilner and Eunice L. Kwak and Jeffrey W. Clark and David P. Carbone and Hongbin Ji and Jeffrey A. Engelman and Mari Mino-Kenudson and William Pao and A. John Iafrate
Journal of Clinical Oncology, ISSN 0732-183X, 03/2012, Volume 30, Issue 8, pp. 863 - 870
Purpose Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene have recently been described in a subset of non-small-cell lung cancers... 
ANAPLASTIC LYMPHOMA KINASE | EML4-ALK | GLIOBLASTOMA | GEFITINIB | FUSION | GENE | ONCOLOGY | MUTATIONS | INHIBITORS | TUMORS | FEATURES | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Protein-Tyrosine Kinases - genetics | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Retrospective Studies | Pyrazoles - pharmacology | Pyridines - therapeutic use | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | In Situ Hybridization, Fluorescence | Proto-Oncogene Proteins - genetics | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Receptor Protein-Tyrosine Kinases - genetics | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Aged | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Drug Screening Assays, Antitumor | Original Reports | Thor9 | Thor2 | Thor12
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Isolation of rare circulating tumour cells in cancer patients by microchip technology
by Nagrath, Sunitha and Sequist, Lecia V and Maheswaran, Shyamala and Bell, Daphne W and Irimia, Daniel and Ulkus, Lindsey and Smith, Matthew R and Kwak, Eunice L and Digumarthy, Subba and Muzikansky, Alona and Ryan, Paula and Balis, Ulysses J and Tompkins, Ronald G and Haber, Daniel A and Toner, Mehmet
Nature, ISSN 0028-0836, 12/2007, Volume 450, Issue 7173, pp. 1235 - 1239
Viable tumour- derived epithelial cells ( circulating tumour cells or CTCs) have been identified in peripheral blood from cancer patients and are probably the... 
CARCINOMA-CELLS | ON-A-CHIP | MULTIDISCIPLINARY SCIENCES | METASTATIC BREAST-CANCER | ENUMERATION | PERIPHERAL-BLOOD | SEPARATION | EXPRESSION | FLOW | MICROFLUIDICS | Microarray Analysis - methods | Neoplastic Cells, Circulating - pathology | Microarray Analysis - instrumentation | Humans | Male | Neoplasms - diagnosis | Cell Separation - methods | Neoplasms - drug therapy | Microfluidics - instrumentation | Neoplasm Metastasis | Neoplasms - blood | Sensitivity and Specificity | Female | Neoplasms - pathology | Microfluidics - methods | Medical research | Semiconductors | Oncology | Medical diagnosis | Cells | Blood | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights